A novel dual NO-donating oxime and c-Jun N-terminal kinase inhibitor protects against cerebral ischemia-reperfusion injury in mice

Dmitriy N. Atochin, Igor Alexandrovich Shchepetkin, Andrey Ivanovich Khlebnikov, Victor I. Seledtsov, Helen Swanson, Mark T. Quinn, Paul L. Huang

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

The c-Jun N-terminal kinase (JNK) has been shown to be an important regulator of neuronal cell death. Previously, we synthesized the sodium salt of 11H-indeno[1,2-b]quinoxalin-11-one (IQ-1S) and demonstrated that it was a high-affinity inhibitor of the JNK family. In the present work, we found that IQ-1S could release nitric oxide (NO) during its enzymatic metabolism by liver microsomes. Moreover, serum nitrite/nitrate concentration in mice increased after intraperitoneal injection of IQ-1S. Because of these dual actions as JNK inhibitor and NO-donor, the therapeutic potential of IQ-1S was evaluated in an animal stroke model. We subjected wild-type C57BL6 mice to focal ischemia (30 min) with subsequent reperfusion (48 h). Mice were treated with IQ-1S (25 mg/kg) suspended in 10% solutol or with vehicle alone 30 min before and 24 h after middle cerebral artery (MCA) occlusion (MCAO). Using laser-Doppler flowmetry, we monitored cerebral blood flow (CBF) above the MCA during 30 min of MCAO provoked by a filament and during the first 30 min of subsequent reperfusion. In mice treated with IQ-1S, ischemic and reperfusion values of CBF were not different from vehicle-treated mice. However, IQ-1S treated mice demonstrated markedly reduced neurological deficit and infarct volumes as compared with vehicle-treated mice after 48 h of reperfusion. Our results indicate that the novel JNK inhibitor releases NO during its oxidoreductive bioconversion and improves stroke outcome in a mouse model of cerebral reperfusion. We conclude that IQ-1S is a promising dual functional agent for the treatment of cerebral ischemia and reperfusion injury.

Original languageEnglish
Pages (from-to)45-49
Number of pages5
JournalNeuroscience Letters
Volume618
DOIs
Publication statusPublished - 8 Apr 2016

Fingerprint

Oximes
JNK Mitogen-Activated Protein Kinases
Reperfusion Injury
Brain Ischemia
Nitric Oxide
Reperfusion
Cerebrovascular Circulation
Stroke
Quinoxalines
Laser-Doppler Flowmetry
Nitric Oxide Donors
Middle Cerebral Artery Infarction
Middle Cerebral Artery
Liver Microsomes
Nitrites
Intraperitoneal Injections
Nitrates
Cell Death
Ischemia
Animal Models

Keywords

  • C-Jun N-terminal kinase
  • Cerebral reperfusion
  • Nitric oxide

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

A novel dual NO-donating oxime and c-Jun N-terminal kinase inhibitor protects against cerebral ischemia-reperfusion injury in mice. / Atochin, Dmitriy N.; Shchepetkin, Igor Alexandrovich; Khlebnikov, Andrey Ivanovich; Seledtsov, Victor I.; Swanson, Helen; Quinn, Mark T.; Huang, Paul L.

In: Neuroscience Letters, Vol. 618, 08.04.2016, p. 45-49.

Research output: Contribution to journalArticle

@article{380beb3a80f145b48b0dbd2b0849e584,
title = "A novel dual NO-donating oxime and c-Jun N-terminal kinase inhibitor protects against cerebral ischemia-reperfusion injury in mice",
abstract = "The c-Jun N-terminal kinase (JNK) has been shown to be an important regulator of neuronal cell death. Previously, we synthesized the sodium salt of 11H-indeno[1,2-b]quinoxalin-11-one (IQ-1S) and demonstrated that it was a high-affinity inhibitor of the JNK family. In the present work, we found that IQ-1S could release nitric oxide (NO) during its enzymatic metabolism by liver microsomes. Moreover, serum nitrite/nitrate concentration in mice increased after intraperitoneal injection of IQ-1S. Because of these dual actions as JNK inhibitor and NO-donor, the therapeutic potential of IQ-1S was evaluated in an animal stroke model. We subjected wild-type C57BL6 mice to focal ischemia (30 min) with subsequent reperfusion (48 h). Mice were treated with IQ-1S (25 mg/kg) suspended in 10{\%} solutol or with vehicle alone 30 min before and 24 h after middle cerebral artery (MCA) occlusion (MCAO). Using laser-Doppler flowmetry, we monitored cerebral blood flow (CBF) above the MCA during 30 min of MCAO provoked by a filament and during the first 30 min of subsequent reperfusion. In mice treated with IQ-1S, ischemic and reperfusion values of CBF were not different from vehicle-treated mice. However, IQ-1S treated mice demonstrated markedly reduced neurological deficit and infarct volumes as compared with vehicle-treated mice after 48 h of reperfusion. Our results indicate that the novel JNK inhibitor releases NO during its oxidoreductive bioconversion and improves stroke outcome in a mouse model of cerebral reperfusion. We conclude that IQ-1S is a promising dual functional agent for the treatment of cerebral ischemia and reperfusion injury.",
keywords = "C-Jun N-terminal kinase, Cerebral reperfusion, Nitric oxide",
author = "Atochin, {Dmitriy N.} and Shchepetkin, {Igor Alexandrovich} and Khlebnikov, {Andrey Ivanovich} and Seledtsov, {Victor I.} and Helen Swanson and Quinn, {Mark T.} and Huang, {Paul L.}",
year = "2016",
month = "4",
day = "8",
doi = "10.1016/j.neulet.2016.02.033",
language = "English",
volume = "618",
pages = "45--49",
journal = "Neuroscience Letters",
issn = "0304-3940",
publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - A novel dual NO-donating oxime and c-Jun N-terminal kinase inhibitor protects against cerebral ischemia-reperfusion injury in mice

AU - Atochin, Dmitriy N.

AU - Shchepetkin, Igor Alexandrovich

AU - Khlebnikov, Andrey Ivanovich

AU - Seledtsov, Victor I.

AU - Swanson, Helen

AU - Quinn, Mark T.

AU - Huang, Paul L.

PY - 2016/4/8

Y1 - 2016/4/8

N2 - The c-Jun N-terminal kinase (JNK) has been shown to be an important regulator of neuronal cell death. Previously, we synthesized the sodium salt of 11H-indeno[1,2-b]quinoxalin-11-one (IQ-1S) and demonstrated that it was a high-affinity inhibitor of the JNK family. In the present work, we found that IQ-1S could release nitric oxide (NO) during its enzymatic metabolism by liver microsomes. Moreover, serum nitrite/nitrate concentration in mice increased after intraperitoneal injection of IQ-1S. Because of these dual actions as JNK inhibitor and NO-donor, the therapeutic potential of IQ-1S was evaluated in an animal stroke model. We subjected wild-type C57BL6 mice to focal ischemia (30 min) with subsequent reperfusion (48 h). Mice were treated with IQ-1S (25 mg/kg) suspended in 10% solutol or with vehicle alone 30 min before and 24 h after middle cerebral artery (MCA) occlusion (MCAO). Using laser-Doppler flowmetry, we monitored cerebral blood flow (CBF) above the MCA during 30 min of MCAO provoked by a filament and during the first 30 min of subsequent reperfusion. In mice treated with IQ-1S, ischemic and reperfusion values of CBF were not different from vehicle-treated mice. However, IQ-1S treated mice demonstrated markedly reduced neurological deficit and infarct volumes as compared with vehicle-treated mice after 48 h of reperfusion. Our results indicate that the novel JNK inhibitor releases NO during its oxidoreductive bioconversion and improves stroke outcome in a mouse model of cerebral reperfusion. We conclude that IQ-1S is a promising dual functional agent for the treatment of cerebral ischemia and reperfusion injury.

AB - The c-Jun N-terminal kinase (JNK) has been shown to be an important regulator of neuronal cell death. Previously, we synthesized the sodium salt of 11H-indeno[1,2-b]quinoxalin-11-one (IQ-1S) and demonstrated that it was a high-affinity inhibitor of the JNK family. In the present work, we found that IQ-1S could release nitric oxide (NO) during its enzymatic metabolism by liver microsomes. Moreover, serum nitrite/nitrate concentration in mice increased after intraperitoneal injection of IQ-1S. Because of these dual actions as JNK inhibitor and NO-donor, the therapeutic potential of IQ-1S was evaluated in an animal stroke model. We subjected wild-type C57BL6 mice to focal ischemia (30 min) with subsequent reperfusion (48 h). Mice were treated with IQ-1S (25 mg/kg) suspended in 10% solutol or with vehicle alone 30 min before and 24 h after middle cerebral artery (MCA) occlusion (MCAO). Using laser-Doppler flowmetry, we monitored cerebral blood flow (CBF) above the MCA during 30 min of MCAO provoked by a filament and during the first 30 min of subsequent reperfusion. In mice treated with IQ-1S, ischemic and reperfusion values of CBF were not different from vehicle-treated mice. However, IQ-1S treated mice demonstrated markedly reduced neurological deficit and infarct volumes as compared with vehicle-treated mice after 48 h of reperfusion. Our results indicate that the novel JNK inhibitor releases NO during its oxidoreductive bioconversion and improves stroke outcome in a mouse model of cerebral reperfusion. We conclude that IQ-1S is a promising dual functional agent for the treatment of cerebral ischemia and reperfusion injury.

KW - C-Jun N-terminal kinase

KW - Cerebral reperfusion

KW - Nitric oxide

UR - http://www.scopus.com/inward/record.url?scp=84959450265&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84959450265&partnerID=8YFLogxK

U2 - 10.1016/j.neulet.2016.02.033

DO - 10.1016/j.neulet.2016.02.033

M3 - Article

VL - 618

SP - 45

EP - 49

JO - Neuroscience Letters

JF - Neuroscience Letters

SN - 0304-3940

ER -